NCT05495958 is a Phase 2, PHASE3 clinical trial of Topical Vitamin D eye drop in Meibomian Gland Dysfunction, sponsored by Shahid Beheshti University of Medical Sciences.

Who is sponsoring NCT05495958?

NCT05495958 is sponsored by Shahid Beheshti University of Medical Sciences.

What drugs are being tested in NCT05495958?

Interventions in NCT05495958: Topical Vitamin D eye drop, Topical placebo eye drop.

What condition does NCT05495958 study?

NCT05495958 studies Meibomian Gland Dysfunction.

Is NCT05495958 still recruiting?

NCT05495958 is currently status unknown. Last updated 10 August 2022.

Last reviewed 2022-08-10 · How we verify

NCT05495958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy and Safety of Topical Vitamin D Drop on Meibomian Gland Function in Patients With Meibomian Gland Dysfunction

Status unknown Phase 2, PHASE3 Last updated 10 August 2022

What this trial tests

Phase 2, PHASE3 trial testing Topical Vitamin D eye drop in Meibomian Gland Dysfunction in 56 participants. Status unknown.

Timeline

25 July 2022

Primary endpoint
30 October 2022

30 December 2022

Quick facts

Lead sponsor	Shahid Beheshti University of Medical Sciences
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	56
Start date	25 July 2022
Primary completion	30 October 2022
Estimated completion	30 December 2022
Sites	1 location across Iran

Drugs / interventions tested

Topical Vitamin D eye drop — full drug profile →
Topical placebo eye drop — full drug profile →

Conditions studied

Meibomian Gland Dysfunction — all drugs for Meibomian Gland Dysfunction →

Sponsor

Shahid Beheshti University of Medical Sciences

Who can join

50 and older, any sex, with Meibomian Gland Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this randomized clinical trial, patients with Meibomian gland dysfunction aged 50 year and more will be enrolled. The Meibomian gland dysfunction diagnosis will confirmed by a cornea specialist. The enrolled patients will be randomly allocated to the treatment and placebo group. The patients in treatment group will receive topical vitamin D every 6 hours daily (25 Microgram/cc or 1000 IU). The control group will receive the same-shape packed drop without vitamin D. The patients in both group will receive the conventional treatment including hot compress and shampoo scrub. The primary outcome is the change in Ocular surface disease index and 5-Item Dry Eye Questionnaire score assessed before the topical treatment and every one-months until 3 months. The secondary outcome measures are Tear breakup time, Schirmer test, Corneal fluorescein staining, Meibomian gland expressibility. The grader and the patients will blind to the study group.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacological, Natural and Emerging Therapies for Meibomian Gland Dysfunction: A Review.
Cooper JM, Mahmoud R, Jennings CJ, Bandamwar K, et al · · 2026 · PMID 41931217 · DOI 10.1007/s40265-025-02241-6

Verify or expand the search:

Other recruiting trials for Meibomian Gland Dysfunction

Currently open trials in the same condition.

NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting
NCT06371300 — Photobiomodulation With REd vs BluE Light (REBEL) · NA · recruiting
NCT06054217 — Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex · Phase 2 · active not recruiting
NCT03652337 — Meibomian Gland Dysfunction Management · NA · active not recruiting

Other Shahid Beheshti University of Medical Sciences trials

Trials by the same sponsor.

NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05495958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
Last refreshed: 10 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing